Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study
- 27 September 2016
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 36 (2) , 451-455
Abstract
Our aim was to evaluate the effectiveness of adalimumab (ADA) during a 24-month study period in patients affected with Behçet’s disease (BD). Clinical and therapeutic data from 100 consecutive BD patients treated with ADA were retrospectively collected and statistically analyzed. At 12-week follow-up, ADA induced clinical efficacy in 81 patients, with a mean time to response of 7.63 ± 3.43 weeks; 25 (30.9 %) patients underwent a disease relapse after 22.17 ± 1.57 months, but treatment adjustments allowed a recovery of efficacy in 11 cases. At 24-month follow-up, 67/100 patients were still on ADA therapy despite concomitant treatments. No differences were identified between ADA monotherapy and co-treatment with DMARDs about efficacy (p = 0.09), time to response (p = 0.61), relapses (p = 0.36), and ADA discontinuation (p = 0.40). No differences existed in patients switched from other tumor necrosis factor (TNF)-α inhibitors about efficacy at 12 weeks (p = 0.13) and rapidity of response (p = 0.93) while relapses (p = 0.01) and ADA discontinuation at 24 months (p = 0.001) were significantly more common. Adverse events occurred in 10 patients. ADA confirmed its effectiveness in BD. Combination therapy with DMARDs seems not significantly superior to monotherapy. Frequency and time to response for ADA was not conditioned by a previous lack or loss of efficacy to other TNF-α inhibitors, but long-term loss of efficacy seemed more likely in patients switched from other anti-TNF agents.Keywords
This publication has 21 references indexed in Scilit:
- New therapeutic solutions for Behçet’s syndromeExpert Opinion on Investigational Drugs, 2016
- Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort studyInternational Journal of Rheumatic Diseases, 2015
- Mucocutaneous Involvement in Behçet’s Disease: How Systemic Treatment Has Changed in the Last Decades and Future PerspectivesMediators of Inflammation, 2015
- Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's diseaseAutoimmunity Reviews, 2015
- Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Behçet’s diseaseRheumatology International, 2013
- Adalimumab for the treatment of Behcet's disease: experience in 19 patientsRheumatology, 2012
- The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration.2010
- EULAR recommendations for the management of Behçet diseaseAnnals of the Rheumatic Diseases, 2008
- Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to Brazilian Portuguese languageClinical Rheumatology, 2006
- Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.1990